Monroe Capital (MRCC) Projected to Post Quarterly Earnings on Monday

Monroe Capital (NASDAQ:MRCC) is anticipated to issue its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.28 per share and revenue of $15.00 million for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Monroe Capital Stock Up 0.7 %

Monroe Capital stock opened at $8.16 on Friday. The company has a current ratio of 4.37, a quick ratio of 4.37 and a debt-to-equity ratio of 1.49. The stock has a 50 day moving average of $8.51 and a two-hundred day moving average of $8.26. Monroe Capital has a twelve month low of $6.97 and a twelve month high of $8.85. The stock has a market capitalization of $176.79 million, a price-to-earnings ratio of 13.60 and a beta of 1.02.

Monroe Capital Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Friday, March 14th will be paid a dividend of $0.25 per share. The ex-dividend date is Friday, March 14th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 12.25%. Monroe Capital’s dividend payout ratio (DPR) is presently 222.22%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. B. Riley cut Monroe Capital from a “neutral” rating to a “sell” rating and set a $7.25 target price for the company. in a research note on Wednesday, December 11th. StockNews.com cut Monroe Capital from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Oppenheimer decreased their target price on Monroe Capital from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, March 4th.

Monroe Capital Company Profile

Monroe Capital Corporation is a business development company specializing in customized financing solutions in senior, unitranche and junior secured debt, subordinated debt financing and to a lesser extent, unsecured debt and equity, including equity co-investments in preferred and common stock and warrants.